Our findings provide evidence that genetic variants in PKD1 and SMAD2 mechanistically underlie the risk of IA, thereby providing supporting evidence that screening for IA in patients with ADPKD and LDS may be beneficial. The gene discussed is PKD1; the disease is autosomal dominant polycystic kidney disease.